Stanley Laman Group Ltd. Has $537,000 Stock Position in Stryker Co. (NYSE:SYK)

Stanley Laman Group Ltd. boosted its stake in shares of Stryker Co. (NYSE:SYK) by 8.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,491 shares of the medical technology company’s stock after buying an additional 112 shares during the period. Stanley Laman Group Ltd.’s holdings in Stryker were worth $537,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of SYK. CX Institutional raised its holdings in Stryker by 3.9% during the 3rd quarter. CX Institutional now owns 3,478 shares of the medical technology company’s stock worth $1,257,000 after buying an additional 130 shares during the period. Swedbank AB raised its holdings in shares of Stryker by 10.9% in the third quarter. Swedbank AB now owns 51,070 shares of the medical technology company’s stock valued at $18,450,000 after purchasing an additional 5,032 shares during the last quarter. McKinley Carter Wealth Services Inc. acquired a new stake in shares of Stryker in the third quarter valued at approximately $208,000. Wolff Wiese Magana LLC raised its holdings in shares of Stryker by 4,288.9% in the third quarter. Wolff Wiese Magana LLC now owns 790 shares of the medical technology company’s stock valued at $285,000 after purchasing an additional 772 shares during the last quarter. Finally, Carderock Capital Management Inc. raised its holdings in shares of Stryker by 13.4% in the third quarter. Carderock Capital Management Inc. now owns 21,316 shares of the medical technology company’s stock valued at $7,701,000 after purchasing an additional 2,514 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on SYK shares. Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday. BTIG Research lifted their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Evercore ISI lifted their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, UBS Group lifted their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.90% of the stock is currently owned by company insiders.

Stryker Trading Up 0.7 %

SYK stock opened at $388.28 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a fifty day moving average price of $377.19 and a two-hundred day moving average price of $366.15. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market cap of $148.02 billion, a price-to-earnings ratio of 50.04, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business earned $3.46 earnings per share. Equities analysts anticipate that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. Stryker’s payout ratio is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.